What is Aldeyra Therapeutics Inc's earnings per share (EPS)?

Aldeyra Therapeutics Inc (ALDX) reported diluted earnings per share of $-0.56 for fiscal year 2025. This represents a 40.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aldeyra Therapeutics Inc Financials

ALDX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Aldeyra Therapeutics Inc (ALDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Aldeyra Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.99x

For every $1 of reported earnings, Aldeyra Therapeutics Inc generates $0.99 in operating cash flow (-$33.3M OCF vs -$33.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-18.5x

Aldeyra Therapeutics Inc earns $-18.5 in operating income for every $1 of interest expense (-$35.3M vs $1.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$35.0M

YoY+41.5%

Aldeyra Therapeutics Inc's EBITDA was -$35.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 41.5% from the prior year.

Net Income

-$33.8M

YoY+39.4%

Aldeyra Therapeutics Inc reported -$33.8M in net income in fiscal year 2025. This represents an increase of 39.4% from the prior year.

EPS (Diluted)

$-0.56

YoY+40.4%

Aldeyra Therapeutics Inc earned $-0.56 per diluted share (EPS) in fiscal year 2025. This represents an increase of 40.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$70.0M

YoY+28.5%

5Y CAGR-2.1%

10Y CAGR+16.9%

Aldeyra Therapeutics Inc held $70.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

60M

YoY+0.9%

5Y CAGR+9.2%

10Y CAGR+20.0%

Aldeyra Therapeutics Inc had 60M shares outstanding in fiscal year 2025. This represents an increase of 0.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-76.5%

YoY+2.2pp

5Y CAGR-13.4pp

10Y CAGR-27.9pp

Aldeyra Therapeutics Inc's ROE was -76.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$25.7M

YoY-46.8%

5Y CAGR+0.8%

10Y CAGR+13.0%

Aldeyra Therapeutics Inc invested $25.7M in research and development in fiscal year 2025. This represents a decrease of 46.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ALDX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$25.7M-46.8%	$48.2M+63.7%	$29.5M-37.7%	$47.3M+5.3%	$44.9M+82.1%	$24.7M
SG&A Expenses	$9.6M-19.3%	$11.9M-10.8%	$13.3M-13.3%	$15.4M+36.3%	$11.3M+13.0%	$10.0M
Operating Income	-$35.3M+41.3%	-$60.1M-40.5%	-$42.8M+31.7%	-$62.7M-11.5%	-$56.2M-54.4%	-$36.4M
Interest Expense	$1.9M-1.1%	$1.9M-7.0%	$2.1M+22.3%	$1.7M-2.8%	$1.7M-8.5%	$1.9M
Income Tax	$0-100.0%	$1K	$0	$0	$0+100.0%	-$479K
Net Income	-$33.8M+39.4%	-$55.9M-48.8%	-$37.5M+39.5%	-$62.0M-7.4%	-$57.8M-53.8%	-$37.6M
EPS (Diluted)	$-0.56+40.4%	$-0.94-46.9%	$-0.64+39.6%	$-1.06+0.9%	$-1.07	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$5.4M-36.1%	$8.5M+14.6%	$7.4M	N/A	$12.4M-16.9%	$15.0M+142.1%	$6.2M
SG&A Expenses	N/A	$2.6M+54.5%	$1.7M-44.6%	$3.0M	N/A	$3.7M+21.7%	$3.0M-5.4%	$3.2M
Operating Income	N/A	-$8.0M+21.3%	-$10.2M+2.5%	-$10.4M	N/A	-$16.1M+10.4%	-$18.0M-91.7%	-$9.4M
Interest Expense	N/A	$476K+1.1%	$471K-2.7%	$484K	N/A	$479K+0.3%	$478K-4.2%	$499K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$7.7M+21.3%	-$9.8M+1.6%	-$9.9M	N/A	-$15.1M+10.3%	-$16.8M-108.5%	-$8.1M
EPS (Diluted)	N/A	$-0.13+18.8%	$-0.16+5.9%	$-0.17	N/A	$-0.25+10.7%	$-0.28-100.0%	$-0.14

ALDX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$72.1M-31.1%	$104.6M-29.5%	$148.3M-18.2%	$181.3M-22.2%	$233.1M+179.7%	$83.4M
Current Assets	$71.8M-31.0%	$104.1M-29.6%	$147.8M-18.3%	$181.0M-22.2%	$232.8M+180.2%	$83.1M
Cash & Equivalents	$70.0M+28.5%	$54.5M-61.8%	$142.8M-1.1%	$144.4M-37.2%	$229.8M+195.1%	$77.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$27.8M-17.2%	$33.6M+17.8%	$28.5M-5.8%	$30.3M+10.5%	$27.4M+14.9%	$23.8M
Current Liabilities	$27.8M+49.5%	$18.6M-16.4%	$22.3M+44.9%	$15.4M+30.5%	$11.8M-5.1%	$12.4M
Long-Term Debt	$0-100.0%	$15.0M	$0-100.0%	$14.9M-3.7%	$15.5M+35.6%	$11.4M
Total Equity	$44.3M-37.7%	$71.0M-40.7%	$119.8M-20.7%	$151.0M-26.6%	$205.7M+245.7%	$59.5M
Retained Earnings	-$484.0M-7.5%	-$450.1M-14.2%	-$394.3M-10.5%	-$356.7M-21.0%	-$294.7M-24.4%	-$236.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$72.1M-7.4%	$77.8M-8.4%	$85.0M-8.8%	$93.2M-10.9%	$104.6M-10.8%	$117.3M-6.9%	$126.0M-10.8%	$141.3M
Current Assets	$71.8M-7.3%	$77.5M-8.4%	$84.6M-8.8%	$92.7M-10.9%	$104.1M-10.8%	$116.7M-7.1%	$125.6M-10.8%	$140.8M
Cash & Equivalents	$70.0M+18.0%	$59.3M+43.9%	$41.2M-18.1%	$50.4M-7.7%	$54.5M-20.0%	$68.1M-4.1%	$71.0M-30.7%	$102.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$27.8M-2.6%	$28.6M-3.8%	$29.7M+0.3%	$29.6M-11.9%	$33.6M+4.3%	$32.2M+16.2%	$27.7M-0.5%	$27.9M
Current Liabilities	$27.8M-2.4%	$28.5M-3.5%	$29.5M+106.7%	$14.3M-23.2%	$18.6M+8.4%	$17.2M-37.8%	$27.6M+27.3%	$21.7M
Long-Term Debt	$0	$0	$0-100.0%	$15.1M+0.7%	$15.0M0.0%	$15.0M	$0	$0
Total Equity	$44.3M-10.1%	$49.2M-10.9%	$55.3M-13.1%	$63.6M-10.4%	$71.0M-16.6%	$85.1M-13.4%	$98.3M-13.3%	$113.4M
Retained Earnings	-$484.0M-1.4%	-$477.5M-1.6%	-$469.8M-2.1%	-$460.0M-2.2%	-$450.1M-3.6%	-$434.3M-3.6%	-$419.2M-4.2%	-$402.3M

ALDX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$33.3M+22.8%	-$43.2M-42.5%	-$30.3M+46.5%	-$56.6M-33.1%	-$42.6M-13.5%	-$37.5M
Capital Expenditures	N/A	N/A	$0-100.0%	$16K+109.0%	$8K	N/A
Free Cash Flow	N/A	N/A	-$30.3M+46.5%	-$56.7M-33.1%	-$42.6M	N/A
Investing Cash Flow	$47.7M+206.3%	-$44.9M-249.7%	$30.0M+200.2%	-$30.0M-383637.3%	-$8K-100.0%	$29.0M
Financing Cash Flow	$1.1M+755.4%	-$171K+86.5%	-$1.3M-204.1%	$1.2M-99.4%	$194.5M+364.2%	$41.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$5.3M+24.5%	-$7.0M+17.9%	-$8.6M+31.4%	-$12.5M-3.6%	-$12.0M-50.9%	-$8.0M+39.7%	-$13.2M-32.6%	-$10.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$16.0M-36.0%	$25.0M+4611.6%	-$554K-107.6%	$7.3M+566.2%	-$1.6M-129.7%	$5.3M+128.9%	-$18.2M+40.0%	-$30.4M
Financing Cash Flow	$0-100.0%	$121K	$0-100.0%	$1.0M+12791.2%	$8K+103.9%	-$197K	$0-100.0%	$18K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ALDX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-76.5%+2.2pp	-78.7%-47.3pp	-31.3%+9.7pp	-41.1%-13.0pp	-28.1%+35.0pp	-63.1%
Return on Assets	-47.0%+6.4pp	-53.4%-28.1pp	-25.3%+8.9pp	-34.2%-9.4pp	-24.8%+20.3pp	-45.1%
Current Ratio	2.58-3.0	5.59-1.0	6.64-5.1	11.78-8.0	19.77+13.1	6.69
Debt-to-Equity	0.00-0.2	0.21+0.2	0.00-0.1	0.10+0.0	0.08-0.1	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-15.6%+2.1pp	-17.7%-2.1pp	-15.6%	N/A	-17.8%-0.6pp	-17.1%-10.0pp	-7.1%
Return on Assets	N/A	-9.9%+1.6pp	-11.5%-0.9pp	-10.7%	N/A	-12.9%+0.5pp	-13.4%-7.7pp	-5.7%
Current Ratio	2.58-0.1	2.72-0.1	2.86-3.6	6.49+0.9	5.59-1.2	6.80+2.3	4.55-1.9	6.50
Debt-to-Equity	0.000.0	0.000.0	0.00-0.2	0.24+0.0	0.21+0.0	0.18+0.2	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Contineum Therapeutics CTNM

$501.8M

I-Mab IMAB

$533.7M

Tectonic Therapeutic Inc TECX

$573.1M

MBX Biosciences Inc MBX

$1.6B

4D Molecular Therapeutics Inc. FDMT

$484.0M

Frequently Asked Questions

Is Aldeyra Therapeutics Inc profitable?

No, Aldeyra Therapeutics Inc (ALDX) reported a net income of -$33.8M in fiscal year 2025.

What is Aldeyra Therapeutics Inc's EBITDA?

Aldeyra Therapeutics Inc (ALDX) had EBITDA of -$35.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Aldeyra Therapeutics Inc have?

As of fiscal year 2025, Aldeyra Therapeutics Inc (ALDX) had $70.0M in cash and equivalents against $0 in long-term debt.

What is Aldeyra Therapeutics Inc's return on equity (ROE)?

Aldeyra Therapeutics Inc (ALDX) has a return on equity of -76.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Aldeyra Therapeutics Inc's operating cash flow?

Aldeyra Therapeutics Inc (ALDX) generated -$33.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aldeyra Therapeutics Inc's total assets?

Aldeyra Therapeutics Inc (ALDX) had $72.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Aldeyra Therapeutics Inc spend on research and development?

Aldeyra Therapeutics Inc (ALDX) invested $25.7M in research and development during fiscal year 2025.

How many shares does Aldeyra Therapeutics Inc have outstanding?

Aldeyra Therapeutics Inc (ALDX) had 60M shares outstanding as of fiscal year 2025.

What is Aldeyra Therapeutics Inc's current ratio?

Aldeyra Therapeutics Inc (ALDX) had a current ratio of 2.58 as of fiscal year 2025, which is generally considered healthy.

What is Aldeyra Therapeutics Inc's debt-to-equity ratio?

Aldeyra Therapeutics Inc (ALDX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aldeyra Therapeutics Inc's return on assets (ROA)?

Aldeyra Therapeutics Inc (ALDX) had a return on assets of -47.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aldeyra Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Aldeyra Therapeutics Inc (ALDX) had $70.0M in cash against an annual operating cash burn of $33.3M. This gives an estimated cash runway of approximately 25 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Aldeyra Therapeutics Inc's Piotroski F-Score?

Aldeyra Therapeutics Inc (ALDX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aldeyra Therapeutics Inc's earnings high quality?

Aldeyra Therapeutics Inc (ALDX) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Aldeyra Therapeutics Inc cover its interest payments?

Aldeyra Therapeutics Inc (ALDX) has an interest coverage ratio of -18.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.